Non-cleavable Linker

Non-cleavable linkers are critical structural components of antibody-drug conjugates (ADCs) because they maintain high plasma stability while controlling intracellular payload release through antibody degradation pathways rather than linker cleavage mechanisms^[1][2]. Mechanistically, these linkers require antigen-mediated internalization followed by lysosomal proteolysis of the antibody component, generating active drug-linker-amino acid metabolites that remain associated with degradation products inside target cells^[1][3]. This release process reduces premature systemic payload liberation and directly influences ADC pharmacokinetics, off-target toxicity, and therapeutic index^[1][2]. In cancer models, non-cleavable linker-based ADCs are primarily effective in tumors with high and relatively homogeneous target-antigen expression because payload release depends on efficient intracellular processing after target engagement^[4]. Compared with cleavable linker systems, non-cleavable linkers generally produce limited bystander killing activity because the released metabolites often display reduced membrane permeability, thereby restricting cytotoxic activity to antigen-positive cells^[4][1]. This distinction is particularly important for experimental ADC design, where linker selection must balance tumor heterogeneity, systemic exposure, and safety requirements^[2]. For research applications, thioether-based non-cleavable linkers such as succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) remain widely used because they provide robust circulatory stability and have been clinically validated in trastuzumab emtansine (T-DM1)^[1][3].